Valuation: Renalytix Ai PLC

Market Cap 13.34M 11.42M 10.65M 9.78M 18.37M 1.28B 18.73M 126M 49.27M 640M 50.07M 48.98M 2.12B P/E 2024
-0.45x
P/E 2025 -1.34x
Enterprise Value 17.94M 15.36M 14.33M 13.15M 24.71M 1.72B 25.19M 170M 66.26M 860M 67.35M 65.88M 2.85B EV / Sales 2024
11,059,330x
EV / Sales 2025 12,499,418x
Free-Float
73.31%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 58 15/03/2018
President 65 30/04/2024
Director of Finance/CFO 68 28/05/2024
Director TitleAgeSince
Chairman 62 05/11/2024
Director/Board Member 58 15/03/2018
Chairman 74 -
Change 5-day change 1-year change 3-year change Capi.($)
+11.48%+33.33% - - 23.25M
-1.75%+2.48%+26.28%-30.02% 18.11B
+4.68%-7.33%-39.72%+98.25% 1.69B
+7.61%-1.59%-43.62%-80.01% 1.02B
+0.67%-0.15%-22.01%+28.18% 985M
+0.16%-0.05%+64.65%-7.23% 779M
+5.55%+1.81%-35.43%-46.60% 704M
-2.07%-7.48%-42.69%-43.27% 577M
+1.47%+0.42%-40.70%-35.88% 443M
+1.07%+2.37%+73.08%+47.65% 428M
Average +2.88%-1.07%-6.69%-7.66% 2.75B
Weighted average by Cap. -0.47%+3.55%+14.43%-19.84%

Financials

2024 2025
Net sales 2.29 1.96 1.83 1.68 3.15 219.02 3.21 21.69 8.46 109.77 8.59 8.41 363.39 3 2.57 2.4 2.2 4.13 287.05 4.21 28.43 11.08 143.86 11.26 11.02 476.27
Net income -33.46M -28.65M -26.73M -24.52M -46.08M -3.2B -46.99M -317M -124M -1.6B -126M -123M -5.31B -20.4M -17.47M -16.3M -14.95M -28.1M -1.95B -28.65M -193M -75.36M -978M -76.6M -74.93M -3.24B
Net Debt 3.86M 3.3M 3.08M 2.83M 5.31M 369M 5.41M 36.53M 14.24M 185M 14.47M 14.16M 612M 4.6M 3.94M 3.67M 3.37M 6.34M 440M 6.46M 43.59M 16.99M 221M 17.27M 16.9M 730M
Logo Renalytix Ai PLC
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Employees
-